U.S. markets open in 9 hours 8 minutes
  • S&P Futures

    -8.00 (-0.18%)
  • Dow Futures

    -54.00 (-0.15%)
  • Nasdaq Futures

    -41.25 (-0.27%)
  • Russell 2000 Futures

    -3.60 (-0.16%)
  • Crude Oil

    +0.38 (+0.45%)
  • Gold

    +1.50 (+0.08%)
  • Silver

    0.00 (0.00%)

    +0.0007 (+0.06%)
  • 10-Yr Bond

    +0.0010 (+0.06%)
  • Vix

    -0.21 (-1.34%)

    -0.0006 (-0.05%)

    -0.2690 (-0.24%)

    +1,030.66 (+1.61%)
  • CMC Crypto 200

    +51.20 (+3.46%)
  • FTSE 100

    +5.57 (+0.08%)
  • Nikkei 225

    -183.05 (-0.63%)

Cellectar Biosciences, Inc. (NASDAQ:CLRB): Are Analysts Right About The Drop In Earnings?

  • Oops!
    Something went wrong.
    Please try again later.
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!

Cellectar Biosciences, Inc.'s (NASDAQ:CLRB) latest earnings announcement in December 2018 revealed that losses became smaller relative to the prior year's level as a result of recent tailwinds Below, I've presented key growth figures on how market analysts perceive Cellectar Biosciences's earnings growth outlook over the next few years and whether the future looks brighter. Note that I will be looking at net income excluding extraordinary items to get a better understanding of the underlying drivers of earnings.

Check out our latest analysis for Cellectar Biosciences

Analysts' outlook for this coming year seems positive, with earnings becoming less negative, arriving at -US$13.4m in 2020.

NasdaqCM:CLRB Past and Future Earnings, April 29th 2019
NasdaqCM:CLRB Past and Future Earnings, April 29th 2019

Although it’s useful to understand the rate of growth each year relative to today’s level, it may be more valuable analyzing the rate at which the company is growing on average every year. The advantage of this approach is that we can get a bigger picture of the direction of Cellectar Biosciences's earnings trajectory over the long run, irrespective of near term fluctuations, fluctuate up and down. To calculate this rate, I put a line of best fit through the forecasted earnings by market analysts. The slope of this line is the rate of earnings growth, which in this case is -17%. This means, we can presume Cellectar Biosciences will chip away at a rate of -17% every year for the next couple of years.

Next Steps:

For Cellectar Biosciences, I've put together three important factors you should look at:

  1. Financial Health: Does it have a healthy balance sheet? Take a look at our free balance sheet analysis with six simple checks on key factors like leverage and risk.

  2. Management:Have insiders been ramping up their shares to take advantage of the market's sentiment for CLRB's future outlook? Check out our management and board analysis with insights on CEO compensation and governance factors.

  3. Other High-Growth Alternatives: Are there other high-growth stocks you could be holding instead of CLRB? Explore our interactive list of stocks with large growth potential to get an idea of what else is out there you may be missing!

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.